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Abstract This randomized controlled health economic
study assesses the cost-effectiveness of the concept of total
disc replacement (TDR) (Charite ´/Prodisc/Maverick) when
compared with the concept of instrumented lumbar fusion
(FUS) [posterior lumbar fusion (PLF) /posterior lumbar
interbody fusion (PLIF)]. Social and healthcare perspec-
tives after 2 years are reported. In all, 152 patients were
randomized to either TDR (n = 80) or lumbar FUS
(n = 72). Cost to society (total mean cost/patient, Swedish
kronor = SEK, standard deviation) for TDR was SEK
599,560 (400,272), and for lumbar FUS SEK 685,919
(422,903) (ns). The difference was not signiﬁcant: SEK
86,359 (-45,605 to 214,332). TDR was signiﬁcantly less
costly from a healthcare perspective, SEK 22,996 (1,202 to
43,055). Number of days on sick leave among those who
returned to work was 185 (146) in the TDR group, and 252
(189) in the FUS group (ns). Using EQ-5D, the total gain in
quality adjusted life years (QALYs) over 2 years was 0.41
units for TDR and 0.40 units for FUS (ns). Based on EQ-
5D, the incremental cost-effectiveness ratio (ICER) of
using TDR instead of FUS was difﬁcult to analyze due to
the ‘‘non-difference’’ in treatment outcome, which is why
cost/QALY was not meaningful to deﬁne. Using cost-
effectiveness probabilistic analysis, the net beneﬁt (with
CI) was found to be SEK 91,359 (-73,643 to 249,114)
(ns). We used the currency of 2006 where 1 EURO = 9.26
SEK and 1 USD = 7.38 SEK. It was not possible to state
whether TDR or FUS is more cost-effective after 2 years.
Since disc replacement and lumbar fusion are based on
different conceptual approaches, it is important to follow
these results over time.
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Introduction
In Sweden, as in many other European countries, total
healthcare costs for society are reported to be approxi-
mately 8% of gross national product [1], and the total costs
for low back pain and also chronic low back pain have been
reported to be substantial [2, 3]. Approximately 80% of
costs attributable to back pain are reportedly indirect costs
while 10–20% can be attributed to direct medical care, and
up to 75% of all costs have been ascribed to those still on
sick leave after 3 months chronic low back pain (CLBP)
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pain in Sweden has been reported to account for 17% of
total healthcare costs to society [5]. Surgery for back pain
accounts for a relatively small but rising part of total
hospital costs, and thereby also health care costs, for back
pain, which may be attributed to expanded indications for
surgery and new surgical techniques.
The gold standard for selected patients today is lumbar
fusion (FUS), aimed at reducing pain, decreasing disability
(including returning to work), and increasing quality of
life. A variety of techniques can be used to perform fusion
surgery; so far no speciﬁc technique has proven to be
superior in a randomly assigned patient population. It has
been reported in several reviews, and also in the compre-
hensive Swedish spine register (‘‘SweSpine’’: http://www.
4s.nu), that average patient satisfaction after fusion surgery
is approximately 70% [6–8]. It is therefore not surprising
that new surgical procedures are introduced almost yearly,
and that patient selection prior to undertaking any type of
lumbar surgery is stressed in the literature [9].
Total disc replacement has gained in popularity in recent
years, although the technique has been known since the
early 1980s [10]. One potential advantage of TDR may be
the removal of a possibly painful disc. Also, restoring and
preserving mobility in the motion segment(s) could theo-
retically minimize risk of future discomfort caused by
progressive degenerative changes in adjacent motion seg-
ments, which in theory may result from unfavorable altered
biomechanics due to fusion [11–14].
When new technologies like TDR are introduced to the
market, it should be in the interest of all parties to eva-
luate whether they are cost-effective—do they provide
more value compared with today’s gold standard? Cost
differences and clinical differences should be compared,
as well as cost-effectiveness/utility, which is often
expressed as cost/quality adjusted life years (QALYs)
gained [15].
This health economic RCT with 2-year follow-up was
conducted at Study Center, the most productive spine
surgery department in Sweden with more than 1,200
elective procedures performed annually for various
degenerative spine disorders. The economic perspectives
addressed were those of society and the healthcare sector.
Clinical results were presented in a recent article in the ESJ
[16], see ‘‘Discussion’’. Follow-up was 2 years. Neither the
study secretary (CB) nor the ﬁrst author of this paper (PF),
were associated with the study department, Stockholm
Spine Center.
The aims of the study were to:
1. Deﬁne and compare costs associated with TDR in the
lumbar spine, and instrumented lumbar FUS.
2. Compare cost-effectiveness/utility using the quality
of life instrument EQ-5D.
Patients and methods
Patients had suffered at least 12 months from what was
understood to be discogenic low back pain in one or two
motion segments between L3 and S1 [16]. Additional
nonspeciﬁc leg pain was allowed. Nonspeciﬁc conservative
treatment had been tried and failed. Diagnosis was mainly
based on medical history, clinical examination, radio-
graphs, and MRI, though some patients had also undergone
preoperative discography and facet blocks in an effort to
identify pain-generating segment(s) [17].
Between 2003 and 2005, a total of 152 selected patients
(age 21–55) suffering from therapy-resistant CLBP were
randomized by means of closed envelope technique to
either TDR (n = 80), or to instrumented lumbar FUS
(n = 72) [16]. See Flow chart Fig. 1, and inclusion criteria
Table 1. For demographics and baseline status, see Table 2.
In the disc replacement group, patients were randomized
to receive one of three prostheses: Charite ´ (n = 26, DeP-
uySpine, Raynham, MA, USA), Prodisc (n = 28, Synthes
Spine, West Chester, PA, USA), or Maverick (n = 26,
Medtronic, Memphis, TE, USA). When TDR was per-
formed, a vascular surgeon prepared the anterior retro-
peritoneal approach, and the spine surgeon removed the
disc, mobilized the segment, and inserted the disc pros-
thesis. Of the 72 fusion procedures, 44 were performed as
an instrumented posterior lumbar fusion (PLF) and 28 as an
instrumented posterior lumbar interbody fusion (PLIF),
152 patients included in the study
Data collected prospectively preoperatively after 1 
and 2 years. No crossovers or drop outs
Instr. lumbar fusion 
(FUS= PLF/PLIF) 
n=72
Total Disc Replacement 
(TDR) 
n=80 
152  patients included in the analyses
Cost Data, 
Databases, Patient records, 
Questionnaires (Cost diary) 
1. Hospital care Stockholm
Spine Center, including:
Physician visits
Physician other interventions
Physical therapist visits
X-ray, CT, MRI
Disc provocation
Facet blocks
Corset 
Surgical procedure
Hospital stay
Reoperation
Rehabilitation
2. Primary care, including visits: 
Physician 
Physical therapist
Chiropractor/Naprapath
3. Back-related drug use
4. Family support
Effect Data in this study,
1. Quality of life, EQ-5D (0-1 max) 
EQ-5D was used for cost-
effectiveness analysis.  
2. Back pain, VAS (0-100 max)
3. Disability, ODI (0-100 max)
4. Self-rating of success (ordinal)
Fig. 1 Comparative health economic analyses were performed
between TDR using either Charite ´, Prodisc or Maverick and
instrumented lumbar FUS, performed either as PLF (posterior lumbar
fusion), or as a PLIF (posterior lumbar interbody fusion). Analyses of
statistical signiﬁcance were performed as Intention to treat, which was
the same as per protocol, as there were no crossovers in this study
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123according to the preference of the surgeon. Instruments
used were the Monarch for PLF, supplemented with
Brantigan cages in case of a PLIF (both implants DePuy-
Spine, Raynham, MA, USA). Approximately 80% (118/
152) of all procedures were performed by one surgeon
(SB). In the current study we compared the ‘‘concepts’’ of
prosthesis and fusion, why we did not compare costs or
cost-effectiveness with regard to the speciﬁc implants/
procedures used. This was because we did not consider it
probable that any procedure would produce relevantly
different results in a 2-year period.
Directly after the ‘‘index procedure’’ (TDR or FUS),
patients in both groups were instructed to be as active and
mobile as possible. A soft orthosis was used for 6 weeks in
the TDR group as it was generally recommended in the
literature at the time of the study. An orthosis was not
considered relevant in the FUS group since all patients
were stabilized using instrumentation. Discharge from the
hospital was determined based on the patient’s ability to
ambulate independently, under oral pain management.
After this ‘‘index episode’’ (index procedure plus inpatient
stay), the operating surgeon standardized the sick leave
period to 2 months for all patients, with 50% leave for an
additional month. After this 3-month period, the patients
had the option to contact either the operating surgeon or the
primary care doctor to assess need for additional sick leave.
Cost data
Direct and indirect costs were identiﬁed, measured, and
valued. In Table 3 costs ‘‘per item’’ are presented. Non-
surgical cost items speciﬁed (injections and blocks inclu-
ded) were added as patients utilized them after the index
episode (surgical procedure). These treatments/diagnostic
procedures were valued using a local ‘‘cost per patient’’
reimbursement system used in Study Center, and were used
also for cost estimations regarding a few surgical reinter-
ventions performed at other centers.
All costs, with the exception for three preoperative
radiographic examinations (one X-ray, one CT-scan, and
one MRI), are included from the index episode and
onwards. Direct cost was deﬁned as costs incurred through
utilization of healthcare resources thus speciﬁed in Table 3,
by each individual patient. Indirect cost was deﬁned as
patient reimbursement to cover work absenteeism in
Sweden (sick leave).
Table 1 Study population
Inclusion criteria Exclusion criteria
Age 20–55 years Spinal stenosis with a need for decompression
Low back pain with or without leg pain for more than 1 year Facet joint arthritis more than mild
If leg pain, LBP should dominate Three or more painful levels on clinical examination
Patients not better after a rehab program scheduled for[3 months No obvious painful level(s) at discography—if performed
Radiographic conﬁrmation of disc degeneration (X-ray, CT, MRI) Isthmic spondylolysis/olisthesis
Oswestry disability index of at least 30 or back pain
(VAS) over 50/100 the week before inclusion
Deg. of spondylolisthesis ([3 mm)
Patients open to the two treatment options Major deformity
Signed informed consent Clinically important osteoporosis
Previous relevant spine procedures
Previous disc/vertebral infections
Spinal tumor
Inability to understand information
Non-Swedish residents (possible problems with follow-up)
Pregnancy
Other medical contraindications
Table 2 Demographics and status at index episode
TDR FUS p
n = 80 n = 72
Women (%) 60 58 ns
Age (SD) 40.2 (8.1) 38.5 (7.8) ns
On sick leave (%) 70 70 ns
Blue collar workers (%) 46 37 ns
Smokers (%) 10 11 ns
Previous spinal surgery (%) 12 11 ns
LBP C2 years duration (%) 79 87 ns
VAS back pain (SD) 62.3 (20.8) 58.5 (21.7) ns
VAS leg pain (SD) 32.8 (26.4) 43.7 (28.2) 0.02
EQ-5D (SD) 0.42 (0.31) 0.36 (0.33) ns
ODI (SD) 41.8 (11.8) 41.2 (14.6) ns
Index episode = TDR or FUS plus postop indoor stay
TDR total disc replacement, FUS fusion
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http://www.scb.se), the Study Center and from the cost
diary [18]. The mailed cost diary, used to assess utilization
of different services, was submitted by patients to the study
secretary (CB) after 1, 3, 6, 12, 18, and 24 months. All
information about part-time or full-time sick leave, as well
as part-time or full-time work (25–50–75–100%), was
converted into full-day equivalents for purposes of analy-
sis. Patients who failed to respond at any of the six speci-
ﬁed follow-up periods were contacted by phone (CB).
Clinical data
Clinical outcome was determined based on data from the
Swedish Spine Register (‘‘SweSpine’’), http://www.4s.nu,
which is gathered by questionnaires mailed to all surgically
treated spine patients in Sweden. All patients were also seen
for clinical follow-up by one of the authors (SR), although
no data were recorded at these visits. Health economic
evaluations commonly use the EQ-5D as the main clinical
outcome measure (0–1-graded scale, all minus values were
transferred to zero, where 0 = ‘‘death’’, and 1 = perfect
quality of life). EQ-5D is a general quality of life instrument
that assesses health status based on ﬁve dimensions:
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression [19]. In addition, clinical outcome was
reﬂected as improvement in back pain (VAS, 0–100) and
disability (ODI, 0–100) [20]. Patient-reported outcome was
also presented using a ﬁve-point ordinal scale: total relief of
pain–much better–better–unchanged–worse.
Analyses
The cost-effectiveness (CEA), in this context the same as
cost-utility (CUA) [21], was estimated using the EQ-5D
instrument. The accumulated QALYs for TDR and FUS
over 24 months were calculated using area under the curve
based on point estimates of QoL at baseline, 12 months,
and 24 months, shown in Fig. 2. The incremental cost-
effectiveness ratio (ICER), i.e., the cost per QALY gained,
was estimated by dividing the difference between all rele-
vant direct and indirect costs associated with the two
procedures by the difference in effects (QALYs). The
ICER indicates the difference in costs per additional effect
unit gained using TDR instead of FUS.
The ICER necessarily relates to ‘‘willingness to pay’’
(WTP) for a QALY in order to determine whether a
treatment strategy is cost-effective, in this case TDR when
compared with FUS [15, 22, 23]. WTP is associated with
the value a purchaser (e.g., the healthcare system) puts on a
QALY. The threshold for WTP for a QALY is not estab-
lished and differs from country to country. In Sweden, a
usually referred range for the value of a QALY is SEK
500,000–700,000 (LFN http://www.tlv.se). This WTP for a
QALY can be derived from the value of a statistical life as
measured in a contingent valuation on road safety in
Sweden [24]. The tables and ﬁgures are denominated in
Swedish kronor (SEK), but costs in EURO and USD are
presented as well in Table 3. 1 EURO = SEK 9.26 and 1
USD = SEK 7.38 (2006 annual exchange rates).
A probabilistic analysis using bootstrapping methods
was undertaken to assess the uncertainty of the data and
results were presented as cost-effectiveness planes [25, 26].
Table 3 Costs per item—2006 currency
Hospital costs
a SEK EURO USD
Physician per visit 2,003 216 271
Other actions by physician
b 501 54 68
X-ray per investigation 600 65 81
CT per investigation 1,500 162 203
MRI per investigation 2,500 270 339
Diagnostic tests
a
Disc injection/episode 11,000 1,188 1,491
Facet injection/episode 11,000 1,188 1,491
Corset 1,000 108 136
Index episode (TDR or FUS)
a
Total disc replacement (TDR) 105,613 11,405 14,311
Instrumented fusion (PLF or PLIF) 107,111 11,567 14,514
Complications/adverse events
a
Debridement/postoperative infection
e 21,029 2,271 2,849
Extraction of implant
e 26,608 2,873 3,605
Refusion due to pain
e 109,317 11,805 14,813
Reoperation abdominal hernia
e 20,185 2,180 2,735
Indoor rehabilitation period
e 41,000 4,428 5,556
Primary care
c
Physician 1,447 156 196
Physical therapist 723 78 98
Physician private 724 78 98
Physical therapist private 1,447 156 196
Chiropractors and naprapaths private 724 78 98
Relatives, cost/hour
Travel, shopping, house cleaning 280 30 38
Medical drug costs according to ‘‘FASS’’
d
Reimbursement 1 day on sick leave
Male 2,397 259 325
Female 2,059 222 279
1 EURO = SEK 9.26 SEK and 1 USD = SEK 7.38
a Costs according to ‘‘cost per patient’’, Stockholm Spine Center.
Index episode = Index procedure (TDR or FUS) plus additional
inpatient stay
b Estimated cost 1/4 of cost/visit
c National board of health and welfare (social styrelsen)
d FASS, a publication with information of drug prizes
e Sensitivity analysis performed. Reoperations merged. Also 3%
discount per year
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effectiveness ratios in probabilistic analysis, net beneﬁts
(NBs) were used to analyze the results. For example, if
both incremental values are negative, the ICER is positive,
but the interpretation of results would be the opposite if
incremental values were positive. Using NBs avoids this
ambiguity. Net beneﬁt is deﬁned as NB = k Q-C, where k
is the WTP for a QALY, Q is the incremental QALYs, and
C is the incremental cost. A positive NB suggests treatment
is cost-effective (depending on uncertainty, here conﬁ-
dence intervals), while a negative NB suggests the oppo-
site. To assess NB, a value must be placed on a QALY; and
a WTP for a QALY of SEK 500,000 (about EURO 54,000;
USD 67,750) was assumed for this study.
The ‘‘intention-to-treat principle’’ was used to guide
statistical analysis, but analysis in this study, with no
crossovers, was equivalent to ‘‘per protocol’’ analysis.
Results after 2 years were reported from the perspective
of cost to society, including both direct costs (healthcare
sector) and indirect costs (loss of productivity due to sick
leave). In addition, costs from a healthcare perspective
were reported separately.
Sensitivity analyses were performed on excluding
reoperations in both groups, also on costs for inpatient
rehabilitation postop, and on discounting.
Statistics
Power calculation
We used the results presented in the Swedish Lumbar
Spine Study [27], and estimated the total cost to society for
lumbar fusion at SEK 700,000 (EURO 75,594; USD
94,851), and 20% less for disc replacement, or SEK
575,000 (EURO 62,095; USD 77,913). Standard deviation
(SD) was estimated from that same study at SEK 250,000
(EURO 26,998; USD 33,875). To achieve 80% power and
a 5% level of signiﬁcance, a total of 64 patients were
required in each group. It was decided to expand the study
groups to 72 patients each to allow for potential dropout.
Power calculation regarding clinical outcome was reported
in a separate study [16], and was in the same range as the
power calculation for this health economic study.
Since improvement and return to work rate are dicho-
tomous variables, we used the McNemar exact test; for
continuous variables, we used the Wilcoxon signed test.
For testing differences between the two groups regarding
costs and other non-normal clinical variables, we used the
Mann–Whitney U test. All baseline data were compared
between the study groups using a signiﬁcance level of 0.05.
To analyze conﬁdence intervals for cost and effect differ-
ences and for ratios, we used the bootstrapping technique
(resampling 10,000 times) [28]. Data were entered into the
SPSS statistical program (version 17.0).
Approval was obtained from the ethics committee at
Karolinska Hospital in Stockholm, and all patients pro-
vided written informed consent.
Results
Follow-up of cost diaries was 100% at 1, 3, and 6 months,
95% after 12 months, 96% at 18 months, and 99% at
24 months. Follow-up of clinical outcome after 1 and
2 years was 100% for returned questionnaires. In both
cases, the protocols may have been missing some answers,
but missing answers were few and we did not detect any
speciﬁc patterns.
Public economic assistance for patients on sick leave
(part- or full-time) or other unrelated public assistance
(part- or full-time) at the time of the index episode involve
various types of reimbursement systems, which made
detailed estimates difﬁcult, but overall amounted to about
70% of patients in both groups, i.e., approximately 30% in
both groups were working part or full time at baseline.
After 2 years, according to the cost diaries, 76% in the
TDR group and 72% in the FUS group were working part-
or full-time (ns). Among those returning to full- or part-
time work, about 20% in both groups had changed to
lighter duties after 2 years. The number of full days of sick
leave (with SD) following the index episode in the TDR
group and the FUS group among those returning to work
full- or part-time was 185 (146) and 252 (189), respectively
(p = 0.129). Number of sick leave days among those who
were working full-time after 2 years in the two groups was
139 (108) and 166 (132), respectively (p = 0.740), while
sick leave days among those returning to part-time work
was 336 (159) and 419 (173), respectively (p = 0.211).
0,43
0,71
0,68
0,69
0,38
0,63
0,0
0,2
0,4
0,6
0,8
1,0
Preop 1 year 2 years
EQ-5D
Area TDR: 0.41
Area FUS: 0.40
Diff: 0.01
Fig. 2 Area under the curve, demonstrating total improvement after
2 years. EQ-5D: 0 = ’’death’’, 1 = ’’perfect quality of life’’. Larger
area indicates better gain in quality of life. Bold and italic total disc
replacement; hatched instrumented fusion
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123Table 4 presents data associated with the index episode
and indoor stay after this episode. Reoperation in the TDR
group was 10/80 patients (10%), and in the FUS group
26/72 patients (38%). Implant removal was carried out on
20/72 patients (28%) in the FUS group.
Costs
Societal perspective
The mean cost/patient (with SD) in the TDR group was
SEK 599,560 (400,272), and in the FUS group, SEK
685,919 (422,903). The difference (with CI) expressed as
TDR minus FUS was not signiﬁcant: 86,359 (-214,332 to
45,605).
Healthcare perspective
The mean cost per patient in the TDR group was SEK
147,750 (73,408), and in the FUS group, SEK 170, 746 (58
290). The difference was signiﬁcant: 22,995 (1,202 to
43,055) Table 5. The costs per patient associated with the
reinterventions in the two groups are presented in Table 6.
Clinical outcome
Qualityoflifesigniﬁcantlyimprovedinbothsurgicalgroups
whencomparingpreoperativestatuswiththesituationatone
and 2 years, TDR showing 0.41 EQ-5D units and FUS
showing 0.40 EQ-5D units, which translates to a nonsigni-
ﬁcant QALY gain of 0.01 units in favour of the TDR group
over 2 years, Fig. 2. Other clinical results were described in
detail in a previous study [16], where after 2 years, if accu-
mulated difference was measured as in this article, no sta-
tistical difference was found between TDR and FUS with
regard toback pain (VAS) ordisability(ODI).Onanordinal
scale (total relief–much better–better–unchanged–worse),
morepatientsintheTDRgroupexperiencedtotalrelieffrom
back pain after 2 years, 30 versus 15% (p = 0.031), while
there was no difference between groups if total relief and
much better were combined Table 7.
Cost-effectiveness and net beneﬁt
The ICER for EQ-5D using TDR instead of instrumented
fusion was SEK 1,863,590 and is illustrated together with
uncertainty in a cost-effectiveness plane, Fig. 3. The mean
ICER was located in the southeast quadrant, indicating that
Table 4 Hospital data (SD)
Index episode TDR FUS p
a
n = 80 n = 72
Intraoperative blood loss, ml
b 560 (400) 444 ns
Operating time, hours 2.3 (0.8) 2.7 (0.6) \0.05
Length of hospital stay, days 4.4 (1.6) 5.9 (1.2) \0.05
a Mann–Whitney U test
b A few patients in the TDR group had an intraoperative bleeding due
to vein injury, with no sequele in either patient
Table 5 Mean cost/patient in the TDR and FUSION group 2 years following treatment start (SEK)
Total disc replacement versus fusion TDR FUS Diff.
a 95% CI
(n = 80) Std (n = 72) Std Bootstrapping
1. Hospital costs index procedure (cost per patient) 105,613 25,688 107,111 15,589 -1,498 (-8,093 to 5,338)
2. Hospital costs after index procedure
b 15,502 24,074 33,347 42,353 -17,845 (-29,111 to -7,078)
b
3. Total hospital costs (1 ? 2)
b 121,115 36,897 140,458 42,253 -19,343 (-32,355 to -6,747)
b
4. Primary/Private Care 24,146 64,793 26,726 28,597 -2,580 (-16,167 to 14,795)
5. Back-related drugs 2,489 3,461 3,562 4,819 -1,073 (-2,458 to 238)
6. Healthcare perspective (direct costs) (3 ? 4 ? 5)
b 147,750 73,408 170,746 58,290 -22,996 (-43,055 to -1,202)
b
7. Family support, housekeeping 12,879 16,114 16,685 21,444 -3,806 (-10,213 to 2,095)
8. Productivity loss (indirect costs) 438,931 371,542 498,488 389,313 -59,557 (-179,503 to 62,816)
9. Societal perspective (direct ? indirect costs) (6 ? 7 ? 8) 599,560 400,272 685,919 422,903 -86,359 (-214,332 to 45,605)
a Minus in the Diff column means that fusion was more costly, however not signiﬁcantly so with exception for
b
b Hospital costs and also Health care costs differed signiﬁcantly between groups due to more reoperations (mostly removal of implants) in the
FUS group
Table 6 Reoperations and costs after 2 years
n % Costs/pat
b
TDR (n = 80) 8 10 7,015
FUS (n = 72) 26
a 36 22,399
bSEK diff (p\0.05) 15,384
a 20/72 (28%) patients in the FUS group had their implants removed,
explaining the high reoperation rate in this group
b SEK
1006 Eur Spine J (2011) 20:1001–1011
123TDR was cost-saving (i.e., less costly) and associated with
a small improvement in QoL, albeit not signiﬁcant com-
pared with FUS. In order to address uncertainty the net
beneﬁt approach was used. This showed that TDR could
not be demonstrated as a cost-effective strategy when
compared with FUS (SEK 91,359; CI -73,643 to 249,114).
Sensitivity analyses
1. Exclusion of all reoperation costs (36% in the FUS and
10% in the TDR group).
2. Calculating in a 3% discount per FU year. Exclusion of
reoperations did not alter the conclusions from a
societal perspective but from the healthcare perspec-
tive, the signiﬁcant cost difference between the study
groups was eliminated, illustrating the impact of
reoperation costs. Discounting resulted in a small but
signiﬁcant cost difference to the advantage of TDR,
see Table 8.
Discussion
We could not demonstrate any difference with regard to
societal costs or cost-effectiveness when comparing TDR
with instrumented lumbar fusion (FUS) in patients suffer-
ing from CLBP since at least 1 year. In a previous study by
Berg et al. (the current study uses the clinical data reported
in that study), the authors could not demonstrate clinical
superiority with regard to any of the two procedures using
pain (VAS), Function (ODI and SF36), and patient satis-
faction, although signiﬁcantly more patients in the TDR
group reported to be totally pain free after 2 years (30 vs.
15%) [16].
From the Societal perspective we found no signiﬁcant
differences in costs after 2 years. From the healthcare
perspective there was a signiﬁcant cost difference in favor
of TDR, mainly due to a higher reoperation rate in the FUS
group (see below). No concept could be demonstrated to be
cost-effective on behalf of the other.
Several studies report that TDR and FUS provide
approximately the same clinical outcome over 2 years [11,
16, 29–31]. However, some authors express serious con-
cerns about using this procedure except in scientiﬁc trials
[11], but others are more optimistic [32]. The ‘‘non-infe-
riority trial’’ comparing Charite ´ with anterior standalone
BAK instrumentation, reports superior outcome both clini-
cally and economically in the disc prosthesis group [33],
Table 7 Clinical results with standard deviations (SD)
Baseline data FU 2 years TDR–FUS p
c
TDR
a FUS
b TDR
a FUS
b
n = 80 n = 72 n = 80 n = 72 2 years diff
e p
Back pain VAS (SD) 62.3 (20.8) 58.5 (21.7) 25.4 (29.8) 29.2 (24.6) 7.6 ns
Function ODI (SD) 41.8 (11.8) 41.2 (14.6) 20.0 (19.6) 23.1 (17.0) 3.7 ns
Total relief of pain (%)
d 24/80 (30) 11/72 (15) 15 0.031
Much better (%)
d 32/80 (40) 35/72 (49) -9n s
Total relief/much better
d 56/80 (70) 46/72 (64) 6 ns
a Total disc replacement
b Lumbar fusion
c MW U test
d Ordinal scale: totally pain free, much better, better, unchanged, worse
e minus in the 2 years diff column, indicates that the difference was in favor of FUS
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Fig. 3 Cost-effectiveness plane illustrating ICER for TDR compared
with FUS. ICER is located in the south-east quadrant, indicating that
TDR was less costly and slightly more effective. However not
signiﬁcantly so. *Difference (D) in costs and effects between TDR
and FUS. Minus in costs and plus in effects favors TDR. Statistics:
Bootstrapping was used. The dotted area represents the uncertainty
(‘‘uncertainty box’’), with representations in all four quadrants,
illustrating the uncertainty in the calculations
Eur Spine J (2011) 20:1001–1011 1007
123but this comparison could be questioned because of the use
in the control group of stand-alone BAK cages, now rec-
ognized as an inferior fusion technique.
We used the EQ-5D instrument to assess QALYs. This
instrument has been shown to be satisfactory for analyzing
health-related quality of life in the ﬁeld of spine surgery
[34] and to be a useful tool for analyzing cost-effective-
ness. In the current study, the minimal gain of 0.01 EQ-5D
units (on a one-point scale) after 2 years make it practically
impossible to conclude that TDR was associated with a
higher gain in QALYs (diff. in costs/diff. in effects
gained 9 time) compared with FUS, even though there
was also a nonsigniﬁcant cost difference in favor of TDR.
The point estimate of the ICER was located in the southeast
quadrant of the cost-effectiveness plane Fig. 3 indicating a
possible advantage for TDR, but the probabilistic analysis
using bootstrapping showed widespread distribution of the
ICERs in all four quadrants why it therefore not signiﬁ-
cantly favored either procedure.
Cost diaries were used to estimate resource utilization,
including number of sick leave days after the index epi-
sode. One reason we did not use information from the
Swedish Social Insurance Agency was a controversy over
principals among the authorities during the study period as
to how the central registers documenting length of sick
leave and other reimbursement systems could be made
available to researchers. However, this was a randomly
controlled trial for which high internal validity can be
assumed, in which we used patient based ‘‘cost diaries’’ on
six different occasions with secretarial back up when
needed, and in addition interviews by a study nurse also on
six different occasions over the 2-year follow-up period,
for which reason we consider the cost comparison between
the two study groups to be valid.
The threshold of SEK 500,000 (EURO 54,000; USD
67,750) for WTP for an extra QALY gained used in the
current study can be debated. Most commonly used WTP
thresholds for a QALY vary between EURO 40,000 and
80,000 [35]. The UK has often used a threshold of GBP
30,000 (EURO 39,000) in health technology appraisals
(here synonymous with health economic evaluations)
conducted by NICE [36]. However, the WTP for a QALY
was not crucial for interpretation of results in this study
since no difference in QALY gain was found between TDR
and FUS.
According to the scientiﬁc literature, the cost-effec-
tiveness of TDR when compared with FUS after 2 years is
not yet established. Guyer et al. [37] tried to assess this
issue using an economic model developed by DePuy Spine,
where lumbar disc prosthesis (Charite ´, DePuy Spine) on
one level was compared with instrumented fusion at
unspeciﬁed levels. They conclude that the disc prosthesis
procedure was probably cost-effective from a hospital
perspective. These results could possibly be considered in
light of the current study, where hospital costs were sig-
niﬁcantly higher in the fusion group, however, mainly due
to more reoperations in the FUS group, which was not the
case in the Guyer study.
Our pre-study power calculation estimates the 2-year
cost to society for FUS at SEK 700,000 (EURO 75,600;
USD 94,850), and 20% less for TDR, or SEK 575,000
(EURO 62,100; USD 77,900). The discrepancy was pri-
marily based on the assumption that patients receiving disc
prosthesis would return to work earlier than fusion patients.
The power calculation proved to be fairly accurate with a
total cost to society of approximately SEK 686,000 for the
FUS group and SEK 600,000 for the TDR group, a dif-
ference of about 13% (ns). In addition, number of sick
leave days (according to cost diaries) was approximately
60 days less in the TDR group (ns). The uncertainty
reﬂected by wide conﬁdence intervals and large standard
deviations, hampered conclusions regarding cost-effec-
tiveness in favor of either treatment strategy from a societal
perspective. Also, this study was not powered to detect
differences in number of sick leave days (post-study
analysis power was found to be 0.54, compared with the
pre assumed and relevant 0.8).
Our results do not provide any information concerning
the cost-effectiveness of spinal surgery as a procedure per
se, i.e., comparison of cost-effectiveness of surgery versus
no surgery in this patient population, using the procedures
addressed in this article. However, the collective data allow
us to estimate potential QALY gain from the data derived
in this study. Assuming that patients remain at the same
Table 8 Sensitivity analyses after 2 years
TDR (n = 80) Std FUS (n = 72) Std Diff 95% CI
a
Healthcare perspective: reoperation costs excluded 140,736 69,650 148,348 42,784 7,611 (-11,992 to 24,783)
Healthcare perspective: discounting 3% over 2 years 147,751 73,408 170,746 58,289 21,636 (1,407 to 40,530)
Societal perspective: reoperation costs excluded 592,546 397,790 663,520 416,132 70,975 (-57,728 to 199,534)
Societal perspective: discounting 3% over 2 years 599,560 400,272 685,919 422,903 81,254 (-40,905 to 204,762)
There was a small but signiﬁcant cost difference in the perspective of the health care sector when discounting with 3% per year
a Bootstrapping
1008 Eur Spine J (2011) 20:1001–1011
123QoL level without surgery, the QALY gain over 2 years
after surgery can be estimated at approximately 0.45 (on a
one-point EQ-5D scale). This gain is similar to the QALY
gain that has been estimated for total hip arthroplasty in
Sweden [38]. Cost-effectiveness can be roughly estimated
by conservatively assuming that initial hospitalization costs
are the only extra cost of surgery (about SEK 140,000).
The ICER of surgery when compared with no surgery
would then be about SEK 340,000. If WTP for a QALY is
assumed to be approximately SEK 500,000 (as in this
study), this estimate can be considered cost-effective and
possibly represents an underestimate of real cost-effec-
tiveness since it does not consider issues such as fewer
days of sick leave. However, if patients who do not
undergo surgery improve due to natural course of disease,
this assumption may be erroneous.
The current study focused on evaluating the cost-
effectiveness of TDR versus FUS. Another interesting issue
to consider is the economic value of spinal surgery as a
procedure per se. One way to address this issue, based on
the information collected for this study, may be to elabo-
rate on potential cost reduction from patients returning to
work after surgery. At baseline about 70% of patients were
not working, while 2 years post-surgery 40% (TDR and
FUS patients combined) of the patients had returned to
work (full- or part-time). Assuming that the patient sample
contains an equal proportion of part- and full-time workers,
average productivity loss for these patients, had they not
been operated, can be calculated as follows: 500 working
days during 2 years *0.7*SEK 1,700 = SEK 595,000. The
average cost over 2 years related to sick leave for the
operated patients in this study was SEK 467,142. Potential
productivity gain from operating would then be SEK
127,858 per operated patient. By multiplying this ﬁgure
with the number of patients in the study (152), the total
estimated value of the productivity gain would be about
SEK 19 million. From this perspective spine surgery could
provide considerable value in terms of productivity gain.
This is a rough calculation based on 2-year data and a
number of assumptions, but we ﬁnd it interesting and
believe it could be further addressed in a separate study that
would also include reimbursement data from the social
insurance agency covering both surgical patients and
nonsurgical patients suffering from the same disorder.
Moreover, others have come up with similar estimates for
back pain patients awaiting surgery and reached the same
interesting hypothesis.
Potential problems with the current study
This was a single center study conducted at the most pro-
ductive spine unit in Sweden with over 1,200 procedures
for degenerative disc disorders performed annually. One
surgeon (SB) performed the index operation in 80% of the
patients, and it is possible that patient selection, although
there were strict inclusion and exclusion criteria to balance
this, and surgical skills play a role, for which reasons the
results achieved in this study therefore may not be gener-
ally replicable elsewhere. However, when comparing
patient demographics, baseline values and clinical outcome
with other studies and also with national registers, this
seems to be less of a concern.
Although the index episode was equally costly for both
TDR and FUS, total hospital costs after 2 years, as well as
total costs to the healthcare sector, were signiﬁcantly
greater in the FUS group. This difference can be ascribed
to a high reoperation rate, 36% in the FUS group (of which
28% was attributed to implant removal as the implant was
diagnosed by the surgeon as a pain generator), when
compared with 10% in the TDR group. In most cases the
indication for reoperation was determined by one surgeon
(SB), who also performed 90% of these procedures.
Obviously, a certain reoperation rate must be expected
after any surgical procedure but considering the single
center perspective, meaning that the external validity of the
decision to reoperate may be called into question; we
performed a sensitivity analysis where all costs for reop-
eration were removed from both groups. The result was
that the cost difference from the perspective of both the
hospital and the healthcare sector disappeared. It is possible
that there is, in general, a higher reoperation rate after
instrumented lumbar FUS when compared with after total
disc prosthesis, but this cannot be ﬁnally concluded from
this study.
The current study compares the conceptual approach
using disc prosthesis (Charite ´, Prodisc and Maverick) with
that of instrumented fusion (PLF and PLIF). The same
costs were assumed for the three prostheses, and a mean
cost was calculated for the two fusion techniques. It is
possible that from a longer perspective, one of these pro-
cedures, and indeed one of these approaches (motion
preservation vs. fusion), will turn out to be superior from
the perspective of cost-effectiveness. This remains to be
seen and is an important reason to continue to follow these
patients for 5, 10, and 15 years, since 2 years may be
considered a short time frame. The two most important
variables with future potential to inﬂuence cost-effective-
ness, as outlined in this study, may be differences in work
capacity, and the need within any group or subgroup for
additional back surgery.
Health economic comparisons between fusion and non-
surgical treatment in patients suffering from CLBP have
been published with somewhat different results [39–42],
and it should be important to evaluate whether TDR could
have advantages/disadvantages from a cost-effectiveness
Eur Spine J (2011) 20:1001–1011 1009
123perspective in this patient population. We therefore con-
sider this RCT-based health economic evaluation with
relevant follow up and no cross-over, comparing the con-
cepts of TDR and FUS, as important. Although cost-
effectiveness could not be demonstrated with regard to any
concept, after 2 years we found no economic argument
against using TDR in selected patients suffering from
CLBP.
Conclusion
1. Societal costs showed no signiﬁcant difference when
compared with TDR and instrumented lumbar FUS
after 2 years. From a healthcare perspective, FUS was
signiﬁcantly more costly, mainly due to a high reop-
eration rate in this group.
2. It was not possible in this study to determine whether
TDR or FUS was more cost-effective for society
within the 2-year time frame, although TDR was
associated with less costs and a very small gain in
quality of life.
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